<PAGE>

                                                                  Execution Copy
                                                                  --------------

                            MANUFACTURING AGREEMENT
                            -----------------------

     THIS MANUFACTURING AGREEMENT (this "Agreement") is made by and between
                                         ---------
AMERICAN BIOSCIENCE, INC., a California corporation ("ABI"), and AMERICAN
                                                      ---
PHARMACEUTICAL PARTNERS, INC., a California corporation ("APP") as of this 20th
                                                          ---
day of November 2001 (the "Effective Date").
                           --------------

                                    RECITALS
                                    --------

A.  ABI has developed and owns the rights to the Product, as defined in Section
                                                                        -------
2.25.
-----

B.  APP has the capability of, and has constructed facilities and equipment
designed for and capable of, manufacturing the Product, and APP desires to
manufacture the Product, or have the Product manufactured upon the terms and
conditions contained herein.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above Recitals, the mutual
covenants and agreements contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto hereby agree as follows:

1.  Incorporation of Recitals.  The foregoing recitals are hereby incorporated
    -------------------------
herein as representations and warranties of the Parties hereto.

2.  Definitions.  For purposes of this Agreement, in addition to other defined
    -----------
terms set forth in this Agreement, the terms set forth below will have the
following meanings:

     2.1 "ABI Parties" means ABI, its Affiliates, its permitted assignees and
          -----------
any other party approved in writing by ABI.

     2.2 "Act" means the Federal Food Drug and Cosmetic Act (21 U.S.C. Section
          ---
301 et. seq.) as amended from time to time.

     2.3 "Action" means any actual or threatened claim, suit, arbitration,
          ------
hearing, inquiry, proceeding, complaint, charge or investigation by or before
any court, government, governmental entity or arbitrator.

     2.4 "Affiliate" means any entity controlling, controlled by or under the
          ---------
common control of APP or ABI, as the case may be. Such entity will be considered
an Affiliate only for the time during which such control exists. For the purpose
of this Agreement, "control" means having, directly or indirectly, the power to
direct or cause the direction of management and policies of such entity. FOR
PURPOSES OF THIS AGREEMENT, APP SHALL NOT BE CONSIDERED AN AFFILIATE OF ABI, AND
ABI SHALL NOT BE CONSIDERED AN AFFILIATE OF APP.

     2.5 [***]

[***] Omitted pursuant to a confidential treatment request. The material has
      been filed separately with the Securities and Exchange Commission.

<PAGE>

     2.6 "APP Parties" or "APP Party" means any of APP, its Affiliates and its
          -----------      ---------
permitted assignees.

     2.7 "APP Standard Manufacturing Costs" means direct and indirect costs,
          --------------------------------
including, without limitation the materials, components, raw materials, labor
and overhead, attributable to production, manufacturing, processing, quality
control, and packaging of the Product.  APP Standard Manufacturing Costs will
not include costs incurred in connection with Bad Batches of the Product, nor
will it include general and administrative expenses.  APP Standard Manufacturing
Costs will be updated at the end of each calendar year for the purpose of
determining the price for the succeeding year.  Except as otherwise contemplated
by this definition or as agreed by the Parties, the APP Standard Manufacturing
Costs will be determined in accordance with GAAP and standard costing principles
as currently practiced by APP.

     2.8 "Bad Batches" means batches of Product, other than those referred to
          -----------
in Section 8.2, which either (i) are lost in production; (ii) are determined by
   -----------
final decision of APP's quality group to be not suitable for final release; or
(iii) or are properly rejected by the ABI Parties under Section 9 of this
                                                        ---------
Manufacturing Agreement.

     2.9 "CGMP(s)" means current good manufacturing practices established under
          -------
the Act and the Regulations.

     2.10 "Chemical Ingredients" means paclitaxel and albumin.
           --------------------

     2.11 "Commercially Reasonable Best Efforts" means the commercially
           ------------------------------------
reasonable efforts that a prudent business person or company would expend in the
normal course of its business to accomplish an important objective, but does not
mean efforts that could, if carried out, have a significant negative impact on
the Party's relevant business unit as a whole.

     2.12 "Competitor"  means a business entity that markets and sells a
           ----------
pharmaceutical product that includes taxanes as an active pharmaceutical
ingredient.

     2.13 "Damages" means any and all losses, liabilities, obligations, costs,
           -------
expenses, damages or judgments of any kind or nature whatsoever (including
reasonable attorneys', accountants' and experts' fees, disbursements of counsel
and other costs and expenses incurred in pursuing or defending claims under this
Agreement.

     2.14 "Effective Date" shall mean the date of this Agreement, as set forth
           --------------
above.

     2.15 "Estimated Purchase Plan" means ABI's estimate of the Product to be
           -----------------------
ordered for the Territory, with the exception of North America for so long as
the License Agreement is in effect, for each rolling 12-month period during the
Term, which estimate will be issued on a monthly basis.

     2.16 "FDA" means the United States Food and Drug Administration or any
           ---
other successor agency whose approval is necessary to market the Product in the
United States and any comparable agency in such other countries in the Territory
where ABI intends to obtain regulatory approval.

<PAGE>

     2.17 "GAAP" means generally accepted accounting practices as in effect in
           ----
the United States applied on a basis consistent with past practice.

     2.18 "Legal Requirement" means any statute, law, ordinance, rule,
           -----------------
regulation, permit, order, writ, judgment, injunction, decree or award issued,
enacted or promulgated by any governmental entity or any arbitrator.

     2.19 "License Agreement" means that certain License Agreement entered into
           -----------------
between ABI and APP dated the same date as this Agreement.

     2.20 "Manufacturing Recall" means a Recall arising from or relating to the
           --------------------
Product that, when manufactured by APP, was adulterated, contaminated or was
otherwise caused by APP's failure to comply with this Agreement of the
Specifications set forth in this Agreement.

     2.21 "NDA" means one or more of the New Drug Applications that ABI files
           ---
for the Product with the FDA, including any supplements or amendments and
510(k)s, and any foreign equivalents.

     2.22 "North America" means the countries of the United States and its
           -------------
territories and possessions, Canada and Mexico.

     2.23 "Parties" means APP and ABI ("Party" meaning one of the Parties).
           -------                      -----

     2.24 "Person" means any natural person, corporation, trust, association,
           ------
company, partnership, joint venture, governmental entity or other entity.

     2.25 "Product" means ABI-007, a cremaphor-free, nano-particle paclitaxel
           -------
formulation [***].

     2.26 "Product Liability Claim" means any Action by a third party and any
           -----------------------
appeal from any Action asserted by a third party with respect to the Product
alleging product liability, product defect, design, manufacturing, packaging or
labeling defect, failure to warn, or any similar action relating to the
formulation, manufacture, use or safety of the Product.

     2.27 "Proprietary Information" means information relating to the Product,
           -----------------------
the properties, composition or structure of the Product or the manufacture or
processing of the Product or the machines used to manufacture or process the
Product or to a Party's business (including, without limitation, reagents,
computer programs, algorithms, names and expertise of employees and consultants,
know-how, formulas, processes, ideas, inventions, whether patentable or not,
schematics and other technical, business, financial, customer and product
development plans, forecasts, strategies and information), whether previously,
currently or subsequently disclosed to the other Party. Technology and
improvements made by or for ABI will be considered Proprietary Information of
ABI. ABI's Proprietary Information shall include ABI Owned Developments. APP's
Proprietary Information shall include APP Owned Developments.

     2.28 "Proprietary Rights" means any and all patent rights, copyrights,
           ------------------
maskwork, trade secret rights and all other intellectual and industrial property
rights.

<PAGE>

     2.29 "Purchase Order" means written orders for the Product issued by any
           --------------
ABI Party and placed with APP.

     2.30 "Regulatory Approval" means (A) with respect to the APP Parties, the
           -------------------
procurement of any registration, permit and approval required by applicable
government authorities for the manufacture of the Product in the Territory, and
(B) with respect to ABI, the procurement of any registration, permit and
approval required by applicable government authorities for the importation,
marketing, sale, distribution, and use with respect to clinical trials of the
Product in the Territory.

     2.31 "Regulations" means the regulations made under the Act, including
           -----------
without limitation those regulations currently contained in Title 21 of the Code
of Federal Regulations, as amended from time to time.

     2.32 "Specifications" means the specifications for the Product and
           --------------
contained active pharmaceutical ingredients, raw materials, components and
packaging, along with manufacturing procedures for the Product, all of which are
set by ABI considering the comments of APP, as may be changed from time to time
by mutual agreement of the Parties. The Specifications in effect as of the
Effective Date are set forth in a document separately counter-signed by both
Parties. The Specifications include without limitation:

           (A) raw material specifications (including approved suppliers,
     proofs, chemical, microbiological and packaging specifications);

           (B) sampling requirements (including lab, chemical and
     microbiological);

           (C) compounding module, including compounding process and major
     equipment;

           (D) intermediate specifications;

           (E) finished Product release criteria;

           (F) stability specifications;

           (G) test methods; and

           (H) packaging, labels and labeling.

     2.33 "Technology" means any and all ideas, techniques, inventions, methods,
           ----------
data, information, formulae, processes, trade secrets, intellectual property,
know-how, and test results, whether patentable or not, and whether or not
reduced to practice, including Proprietary Rights, owned, controlled or
otherwise in possession of or used by ABI as of the date of this Agreement, or
during the term of this Agreement and necessary or useful to make, have made,
develop, have developed, use, import, market, offer for sale or sell the
Product.

     2.34 "Term" means the initial Term (as defined in Section 12) and any
           ----
Extension or Extensions (as defined in Section 12) to the initial term.
                                       ----------

<PAGE>

     2.35 "Territory" means the entire world.
           ---------

3.  Manufacture and Supply.
    ----------------------

     3.1 Subject to the terms, conditions and provisions of this Agreement, APP
hereby covenants and agrees that during the Term it will manufacture and sell
the Product to the ABI Parties as required by the ABI Parties for resale in the
Territory, with the exception of North America to the extent the Product is
licensed to APP pursuant to the License Agreement, and, for as long as APP
complies with its obligations under this Agreement, ABI hereby grants APP:

           (A) the exclusive right to manufacture the Product for resale in
     North America for a period of three years, after which time such right will
     be non-exclusive for the remainder of the Term; and

           (B) a non-exclusive right to manufacture the Product for resale in
     the remainder of the Territory.

           (C) Notwithstanding Section 3.1(A), in the event APP fails to make a
                               --------------
     milestone payment pursuant to the terms of Section 9 of the License
     Agreement for one or more indications, APP's license to manufacture the
     Product for that indication related to the declined milestone payment shall
     become non-exclusive.

     3.2 Notwithstanding Section 3.1, APP's obligation to sell the Product to
parties that ABI approves in writing, will be subject to APP applying reasonable
credit standards consistent with APP's standard practice.

     3.3 APP will manufacture the Product solely for (A) the ABI Parties and (B)
the APP Parties so long as the License Agreement remains in effect. If there are
shortages of Chemical Ingredients (as defined in Section 5) or if capacity
                                                 ---------
limitations of the APP facilit(ies) indirectly or directly lead to a shortage in
the supply of manufactured Product, a fraction of the total manufactured Product
will be allocated by APP to each of the ABI Parties and to the APP Parties (each
a "Distributor") as follows:
   -----------

           (A)  [***]

           (B)  [***]

                (1)  [***]

                (2)  [***]

                (3)  [***]

                (4)  [***]

     3.4 APP will:

<PAGE>

           (A) obtain and maintain such approvals and licenses as may be
     required for the manufacture of the Product for commercial sale in the
     Territory;

           (B) have such facilities, resources, and personnel, and such industry
     expertise, as may be required for it to manufacture such quantities of the
     Product as may be required hereunder;

           (C) manufacture, test, supply, package, store, ship, deliver, and
     otherwise handle the Product in compliance with the terms and conditions of
     this Agreement, the Specifications, cGMPs, the Act, the Regulations, the
     rules and regulations of the FDA, applicable NDAs and any and all other
     applicable Legal Requirements, including any and all approvals required for
     the manufacture of the Product after FDA approval is obtained;

           (D) set batch sizes in accordance with relevant economic factors and
     APP's standard manufacturing practice;

           (E) keep true, accurate and complete books, records, reports and
     accounts in connection with or relative to the Product, and the
     manufacturing, testing, production, supply, packaging, storage, shipment,
     delivery and handling of the Product, as well as any other books and
     records as may be required from time to time by applicable law, rules and
     regulations; and

           (F) as requested by ABI, provide reasonable warehousing, distribution
     and transportation functions with respect to the Product on behalf the ABI
     Parties and ABI will reimburse APP for APP Internal Costs with respect to
     such activities performed on ABI's behalf as requested by ABI.

     3.5 Subject to the provisions in the License Agreement, ABI will be solely
responsible for obtaining any Regulatory Approvals relating to the marketing of
the Product purchased by the ABI Parties under this Agreement, including but not
limited to, drug approval applications.

     3.6 ABI, or any designee of ABI, will have the right at any time upon prior
reasonable notice and during regular business hours to inspect and examine APP's
facility(ies) used in connection with and relative to the Product and the
manufacturing, testing, supply, packaging, storage, shipment, delivery or
handling of the Product. To minimize disruption to APP's normal operations,
neither ABI nor its designee may perform more than one such audit per facility
per calendar year. If a facilities audit reveals a material manufacturing
problem, ABI will have the right to re-inspect and examine APP's facilities
twice in the following 12-month period.

     3.7 ABI will have the right, in conjunction with any manufacturing audit,
to audit and inspect any and all documents and records related directly to (A)
APP's manufacture and supply of the Product, and (B) APP's performance under
this Agreement with respect to the manufacture and supply of the Product. APP
will also permit representatives of any governmental authority in the Territory,
including, but not limited to, the FDA or its agents to visit and inspect any
and all facilities used in the manufacturing, testing, processing, packaging, or
shipping of the Product. This right for ABI and the FDA includes access to audit
any and all documents and records relating to APP's performance under this
Agreement.

<PAGE>

     3.8 Prior to commencing manufacturing any batch of the Product, APP will
designate whether the batch is being manufactured for the ABI Parties or for the
APP Parties.

     3.9 Except to the extent otherwise provided in this Agreement, APP will not
give any more favorable treatment to itself than it does to the ABI Parties with
respect to the Product.

4.  Transfer of Technology; Improvements.  ABI will convey and disclose in
    ------------------------------------
tangible form to APP, as soon as reasonably practicable after the Effective Date
and throughout the term of this Agreement, all Technology.  Each Party agrees to
as soon as reasonably practicable promptly disclose in tangible form to the
other Party all modifications and improvements made to the Technology during the
term of this Agreement.  APP will immediately transfer to ABI all right, title
and interest in and to any process, product, composition, or product-by-process,
or any improvements thereto, including inventions ("Developments"), made by the
APP Parties using ABI's processes or outputs ("Processes") (collectively, the
"ABI Owned Developments"). From and after their development, the ABI Owned
Developments will be included within the scope of the license granted to APP
under this Agreement. APP will own any Developments made by APP or its assignees
using any process or output other than the Processes, provided such Developments
are developed solely by APP or its assignees without any input from ABI or any
of its employees, including Patrick Soon-Shiong. Any Developments that are
developed solely by APP without using any Processes are referred to as the "APP
Owned Developments." APP may take whatever steps it deems necessary to protect
its rights in the APP Owned Developments.  APP further grants to ABI, subject to
Section 12.7, a perpetual, royalty-free license to use all of the APP Owned
------------
Developments that are used or needed by APP in the manufacture or
commercialization of the Product.

5.  Chemical Ingredients.  Promptly following the Effective Date, ABI will use
    --------------------
and continue to use commercially reasonable efforts to identify at least two
suppliers of each Chemical Ingredient that have obtained or that ABI reasonably
believes will seek and obtain FDA approval, and shall diligently seek approval
as part of its NDA to use such sources. APP will exclusively order and purchase
all Chemical Ingredients used by APP to manufacture the Product for itself or
for the ABI Parties from those sources.

6.  Orders.  By the end of the first week of each month of the Term, ABI will
    ------
send APP an Estimated Purchase Plan behalf of the ABI Parties.  The Parties
acknowledge and agree that the Estimated Purchase Plan is an estimate only and
is not binding upon ABI, except that the Estimated Purchase Plan for the next
three months will become binding on both Parties.  APP shall not be obligated to
supply any quantity of Product earlier than 90 days following the placement of
the Purchase Order for such Product.  APP will use Commercially Reasonable Best
Efforts to fulfill any Purchase Order for the Product but will not be obligated
to fill any Purchase Orders for the Product that in the aggregate exceed the
amounts supplied in the previous full calendar year by more than 15%.  If the
demand for the Product is believed to be greater than the 15% annual increase
contemplated by this Section 6, the Parties will use their best efforts to reach
                     ---------
agreement with respect to the capacity requirements that APP must provide to
fulfill such requirements and the amount of time APP will have to increase its
capacity to meet the increased requirements.  ABI shall give APP written notice
no later than 18 months before the ABI Parties contemplate selling the Product
outside North America.  At such time, ABI shall estimate the quantity of Product
ABI believes it will need in the 12 months following launch in such territory

<PAGE>

and will update that estimate no less often than every six months.  Upon
commencement of sales in such territory, the estimates shall be included in the
Estimated Purchase Plan.

7.  Price and Payment.
    -----------------

     7.1 With the issuance by ABI Parties of a Purchase Order, ABI shall
designate whether (and, as applicable, what portion of) the ordered Product
shall be used for clinical trials or commercial sale. The price per unit of
Product to be charged to the ABI Parties by APP for use in clinical trials will
be [***]. The price per unit of Product to be charged to the ABI Parties by APP
for commercial sale shall be [***]. APP shall purchase all Chemical Ingredients
for Product sold to ABI Parties for clinical trial use. APP shall order, but ABI
shall pay for, all Chemical Ingredients for Product for commercial sale by ABI
Parties. The prices and delivery of the Product will be made Ex-Works at APP's
manufacturing site.

     7.2 The APP Standard Manufacturing Costs will be subject to an adjustment
at the end of each calendar year that this Agreement is in effect for the next
calendar year to account for any cost increases or cost decreases (which must be
reasonably documented by APP to ABI) in any of the components of the cost with
the exception of Chemical Ingredients. APP will be entitled at any time during
the Term to increase the Non-Commercial Price to account for increases, and
shall decrease the Non-Commercial Price to account for decreases, (which must be
reasonably documented by APP to ABI) in the cost of Chemical Ingredients.

     7.3 APP will issue an invoice to the relevant ABI Party for each Purchase
Order, based upon and reflecting the applicable price.  Invoices will be issued
upon release of the Product and payment must be made, net 30 days after receipt
by the relevant ABI Party of an invoice, so long as each Purchase Order and
invoice complies with the terms and conditions of this Agreement.
Notwithstanding the foregoing, if any order of the Product is shipped in advance
of its original requested shipping date, APP will not invoice for that order
until its original requested shipping date.

     7.4 APP will look solely to the party issuing the Purchase Order for
payment but, subject to Section 9, if an ABI Party fails to pay APP within
                        ---------
thirty days of receipt of an invoice, APP will not be obligated to ship any more
Product to that ABI Party until the invoice is paid in full.

     7.5 The Parties agree to handle the costs associated with Bad Batches of
the Product manufactured for ABI Parties as follows:

           (A)  [***].

           (B)  [***].

           (C)  [***].

           (D)  [***].

8.  ABI Regulatory Filings.
    ----------------------

<PAGE>

     8.1 APP will reasonably cooperate with ABI with respect to (A) all filings
and other submissions made by ABI with the applicable governmental agency,
department or other body regarding or relating to the Product and (B) ABI's
efforts to obtain all Regulatory Approvals to develop, test, market, and
distribute the Product in the Territory. Without limiting the foregoing, APP
will provide ABI with such data monitoring support and data analysis support
related to manufacturing issues as ABI may reasonably request. All data and
information relating to such support will be the property of ABI and may be used
by ABI, at no cost to ABI, in such manner as ABI determines.

     8.2 In any Territory where the ABI Parties are selling and marketing the
Product, APP will prepare and submit a chemistry, manufacturing and controls
(CMC) section to any regulatory agency as reasonably requested by ABI, or
analogous section in various countries. Notwithstanding anything to the contrary
in this Section, such CMC will be owned by and will be the Proprietary
Information of ABI. Subject to the provisions of, and during the pendency of,
the License Agreement, the cost of any Batches manufactured by APP for
Regulatory Approval in North America shall be shared equally by the Parties. Any
Batches manufactured by APP for Regulatory Approval outside of North America
shall be bought and paid for by ABI at APP Standard Manufacturing Cost.

     8.3 If either Party becomes aware of any product or activity of any third
party that involves or may involve infringement or other violation of any
Technology, that Party must promptly notify the other Party in writing of the
infringement or violation. ABI may in its discretion take or not take whatever
action it believes is appropriate. APP will fully cooperate with ABI with
respect to bringing any action, including joining as a party to the suit, if
necessary, supplying essential documentary evidence and making essential
witnesses then in its employ available.

9.  Rejected Product.
    ----------------

     9.1 The relevant ABI Party will inspect each lot of the Product for
compliance with the Specifications upon receipt. If within 60 days after receipt
of the Product the ABI Party notifies APP in writing that it does not meet the
Specifications as determined by the ABI Party's testing and inspection of the
Products, APP will replace the Product, subject to Section 9.2, at APP's expense
                                                   -----------
within 45 days of such notice. APP will pay for shipping charges to deliver such
replacement Products to ABI or its designee.

     9.2 If APP disputes the ABI Party's rejection of all or part of any
shipment of the Product as set forth in Section 9.1, it will notify the ABI
                                        -----------
Party in writing within 10 days of receipt of ABI's rejection notice. If such
dispute is not resolved by mutual agreement of the Parties within 60 days of the
ABI Party's notice, such dispute will be resolved by an independent, FDA-
approved testing organization or consultant of recognized repute within the U.S.
pharmaceutical industry, to be mutually designated by the Parties, the
designation of which will not be unreasonably withheld or delayed by either
Party. The determination by the testing entity of the Products' material
compliance or material non-compliance with the Specifications will be final and
binding upon the Parties. The fees and expenses of the testing entity making the
determination will be paid by the Party against which the determination is made.
If the testing entity determines that part or all of the shipment does not
materially comply with the

<PAGE>

Specifications, APP will, at the relevant ABI Party's election, replace the
Product at APP's expense or credit amounts already paid by the ABI Party within
30 days of such determination.

10.  Adverse Experience Reporting; Recalls.
     -------------------------------------

     10.1 Each Party will report to the other Party any information of which it
becomes aware concerning any adverse drug experience in connection with the use
of the Product, including the incidence and the severity thereof.  ABI will
provide to APP copies of any reports submitted to the FDA relating to any
adverse drug experiences that ABI determines to be significant.

     10.2 If ABI is required to initiate, or otherwise in its discretion decides
to initiate, a recall, withdrawal or field correction (collectively, a "Recall")
                                                                        ------
of the Product in the Territory, ABI will notify APP and provide a copy of its
proposal with respect to such Recall, including the Recall letter, for APP's
review prior to ABI's initiation of the Recall. If APP independently believes
that a Recall of the Product in the Territory may be necessary or appropriate,
it must notify ABI, and the parties must fully cooperate with each other
concerning the necessity and nature of the Action.

     10.3 ABI will be responsible for all Recall activities with respect to
Recall of the Product. APP will reasonably cooperate with ABI in connection with
any Recall. Each Party will maintain complete and accurate Recall records
relating to the Product for any periods that are required by any Legal
Requirement.

     10.4 The fees, costs and expenses of any Recall (collectively, the "Recall
                                                                         ------
Expenses") of the Product will be apportioned between the Parties as follows:
--------

           (A) Except as provided in Section 10.4(C)ABI will pay all Recall
     Expenses related to Recalls of the Product sold by ABI Parties.

           (B) Except as provided in Section 10.4(C) the Parties shall share
     50%/50% all Recall Expenses related to Recalls of the Product sold by the
     APP Parties in the Territory;

           (C) If the Recall is a Manufacturing Recall as determined by an
     independent third party, then APP will pay all Recall Expenses.

11.  Product Liability.
     -----------------

     11.1 For so long as ABI is conducting clinical trials of the Product or
commercially marketing and selling the Product, it must maintain product
liability insurance with respect to the Product, with a reputable carrier, in
the amounts set forth in Exhibit A, naming APP and its Affiliates as additional
                         ---------
insureds.

     11.2 For so long as APP is manufacturing and selling the Product, it must
maintain product liability insurance with respect to the Product, with a
reputable carrier, in the amounts set forth in Exhibit B hereto, naming ABI and
                                               ---------
its Affiliates as additional insureds.

<PAGE>

     11.3 Each Party must notify the other Party as promptly as practicable if a
Product Liability Claim is commenced or threatened against any Party. Each Party
must cooperate with the other Party in connection with any Product Liability
Claim that is commenced or threatened against the other Party.

     11.4 If a Product Liability Claim is asserted against both Parties, each
such Party will have the right to designate counsel to defend itself in such
Product Liability Claim. If a Product Liability Claim is brought against one
Party but not the other Party, the named Party will (subject to Section 11.5)
                                                                ------------
have absolute control of litigation, except that:

           (A) the other Party may appoint counsel to participate in the defense
     of such Product Liability Claim if the named Party reasonably determines
     that the participation would not adversely affect the Attorney-Client
     Privilege; and

           (B) if the litigation could reasonably be expected to have an adverse
     effect on the development and commercialization of the Product, the named
     Party will consult with the other Party regarding the conduct of the
     litigation if the named Party reasonably determines that the cooperation
     would not adversely affect the attorney-client privilege.

     11.5 Neither Party shall agree to a settlement of any Product Liability
Claim without the consent of the other Party, which consent may not be
unreasonably withheld or delayed, if the settlement:

           (A) would have an adverse effect on the development or
     commercialization of the Product; or

           (B) would otherwise have a material adverse effect on the other
     Party.

     11.6 Each Party will be solely responsible for any Damages payable by such
Party following final judgment or settlement of any Product Liability Claim
arising from use or sales of the Product in North America (collectively,
"Product Liability Costs") that arise directly from or relate directly to the
 -----------------------
gross negligence, fraud or intentional misconduct of that Party, and must
promptly pay or reimburse the other Party if the other Party pays or incurs any
Product Liability Costs.

12.  Term and Termination.
     --------------------

     12.1 This Agreement will commence on the Effective Date and will terminate
on the 10th anniversary hereof (the "Initial Term"). ABI may extend this
                                     ------------
Agreement after the Initial Term for successive two-year terms (an "Extension")
                                                                    ---------
by giving APP written notice of its election to extend this Agreement six months
prior to the termination of the Initial Term of any Extension.

     12.2 The non-defaulting Party may immediately terminate this Agreement if
the other Party:

           (A) commits a material breach or default ("Breach") under this
     Agreement, which Breach is not remedied within 60 days after the receipt of
     written notice of the Breach by the

<PAGE>

     Party in Breach (except as to the payment of money by ABI, for which the
     notice period will be 10 days). Notwithstanding the foregoing, if the
     Breach is not curable in 60 days, and the breaching or defaulting party in
     good faith notifies the other Party in writing prior to the 60 days that it
     is initiating cure of the Breach, and initiates cure of such Breach within
     60 days and in good faith continues to attempt to cure the Breach, then
     this Agreement shall not be terminated pursuant to this Section 12.2(A);
                                                             ----------------

           (B) has made a material misrepresentation of any representation or
     warranty contained in this Agreement;

           (C) has a permanent or temporary restraining order, preliminary
     injunction or other order granted against it by a court or authority
     enjoining or restricting the manufacture and/or distribution of the Product
     as contemplated hereby in the Territory. Notwithstanding the foregoing, if
     any such order results or would foreseeably result in a decline of 10% or
     less of units of Product manufactured by APP as compared to the prior
     calendar year's number of units of Product manufactured by APP, then this
     Agreement shall not be terminated pursuant to this Section 12.2(C).

           (D) The right of a Party to terminate this Agreement provided in this
     Section 12.2 will not be affected in any way by its waiver of, or failure
     ------------
     to take such action with respect to, any previous default.

     12.3 In addition to its right to terminate this Agreement, if APP fails to
supply the Estimated Purchase Plan Requirements, ABI may, at its option, choose
to make this Agreement non-exclusive.

     12.4 Following a 60-day period after written notice to cure such
condition, this Agreement may be terminated by either ABI or APP if the other
Party:

           (A) does not pay its debts generally as they become due, or is unable
     to pay its debts generally as they become due;

           (B) has or has instituted against it any proceeding seeking to
     adjudicate it bankrupt or insolvent, or seeking liquidation, winding up,
     reorganization, arrangement, adjustment, protection, relief or composition
     of it or its debts under any law relating to bankruptcy, insolvency or
     reorganization or relief of debtors;

           (C) makes a general assignment for the benefit of creditors;

           (D) seeks the entry of an order for relief or the appointment of a
     receiver, liquidator, sequestrator, trustee, custodian or similar official
     for it; or

           (E) takes advantage of any other law or procedure for the protection
     of creditors.

     12.5 Termination is not the sole remedy under this Agreement, and whether
or not termination is effected, all other remedies remain available to each
Party.

<PAGE>

     12.6  If ABI terminates the License Agreement, ABI will have the right, at
its option, to terminate this Agreement.

     12.7  Upon termination by APP under Section 12.2 or 12.4, ABI's license to
                                         ------- ----    ----
APP Owned Developments shall also terminate.

13.  Confidentiality.
     ---------------

     13.1  Each Party recognizes that the other Party holds its Proprietary
Information as important.  In particular, each Party recognizes that the other
Party's Proprietary Information (and the confidential nature thereof) is
critical to the other Party's business and that neither Party would enter into
this Agreement without assurance that such information and the value thereof
will be protected as provided in this Section 13 and elsewhere in this
                                      ----------
Agreement.

     13.2  Each Party must, therefore:

           (A)  Hold the other Party's Proprietary Information in confidence and
take reasonable precautions to protect the Proprietary Information (including,
without limitation, no less than all precautions that it employs with respect to
its own confidential materials);

           (B)  not divulge (except pursuant to a sublicense expressly
authorized in this Agreement) the other Party's Proprietary Information or any
information derived therefrom to any third person; and

           (C)  not make any use whatsoever at any time of the other Party's
Proprietary Information except for purposes of and expressly authorized in this
Agreement.

     13.3  Any employee given access to any Proprietary Information must have a
legitimate "need to know" and must be bound in writing to maintain the
confidence of information to which it is given access.

     13.4  Without granting any right or license, the disclosing Party agrees
that the foregoing restrictions will not apply with respect to information that
the receiving Party is able to demonstrate by competent evidence:

           (A)  is in or (through no improper action or inaction by the
receiving Party or any Affiliate of the receiving Party or its agents or
employees) enters the public domain (and is readily available without
substantial effort);

           (B)  was rightfully disclosed to it by another person without
restriction; or

           (C)  was independently developed by it by persons without access to
such information and without use of any of the disclosing Party's Proprietary
Information.

     13.5  Each Party's obligations under this Section 13 will terminate five
                                               ----------
years after the date of termination or expiration of this Agreement. The Parties
recognize and acknowledge that prior to the Effective Date of this Agreement,
each Party has received the other Party's

<PAGE>

Proprietary Information and each hereby agrees to protect the Proprietary
Information to the same extent as set forth in this Section 13.
                                                    ----------

     13.6  Immediately upon termination or expiration of this Agreement, each
Party will turn over to the other Party all Proprietary Information of the other
Party and all documents or media containing any Proprietary Information and any
and all copies or extracts thereof.

     13.7  Each Party acknowledges and agrees that due to the unique nature of
Proprietary Information, there can be no adequate remedy at law for any breach
of each Party's obligations under this Section 13, that any breach may result in
                                       ----------
irreparable harm to the disclosing Party, and therefore, that upon any breach or
any threat of breach, the disclosing Party will be entitled to appropriate
equitable relief (without the posting of any bond) in addition to whatever
remedies it might have at law in connection with any breach or enforcement of
the receiving Party's obligations under this Agreement or the unauthorized use
or release of any Proprietary Information.


14.  Use of Brand Names.
     ------------------

     14.1  APP has the right and license to use any brand name included in an
NDA that is approved by the FDA for the Product ("ABI Brand Names") in
                                                  ---------------
connection with labeling the Product manufactured by APP under this Agreement
and other related manufacturing procedures. Any use by APP of ABI Brand Names
will be subject to ABI's prior approval.

     14.2  In connection with its use of ABI Brand Names, APP must:

           (A)  not take any action (or refrain from taking any action) that
could impair or dilute the value of any ABI Brand Names; and

           (B)  reasonably cooperate with ABI in connection with any Action
relating to the use by ABI (or its licensees, including APP) of any ABI Brand
Names that APP is using.

15.  Indemnification; Incidental And Consequential Damages.
     -----------------------------------------------------

     15.1  APP agrees to indemnify, defend and hold harmless the ABI Parties
from any Damages incurred by or assessed against the ABI Parties resulting from
a third party claim caused by or alleged to be caused by:

           (A)  APP's failure to perform any of its obligations under this
Agreement;

           (B)  any breach of or inaccuracy in any representations or warranty
made by APP in this Agreement;

           (C)  any Product Liability Claim arising from the gross negligence,
fraud or intentional misconduct of APP or any APP Affiliate; and

<PAGE>

           (D)  any Product Liability Claim directly resulting from the use of
the Product that, when manufactured by APP, was adulterated or contaminated, or
was otherwise caused by APP's failure to comply with this Agreement or the
Specifications.

     15.2  ABI agrees to indemnify, defend and hold harmless the APP Parties
from any Damages incurred by or assessed against the APP Parties resulting from
a third party claim caused by or alleged to be caused by:

           (A)  ABI's failure to perform any of its obligations under this
Agreement;

           (B)  any breach of or inaccuracy in any representations or warranty
made by ABI in this Agreement;

           (C)  any Product Liability Claim arising from the gross negligence,
fraud or intentional misconduct of ABI or any ABI Affiliates; and

           (D)  any Product Liability Claim directly resulting from the use
and/or sale of the Product outside North America except for those covered in
Section 15.1(C) or Section 15.1(D).

     15.3  Except with respect to APP Owned Developments and ABI Owned
Developments, ABI further indemnifies APP for any proceedings instituted by or
on behalf of a third party based upon a claim that the manufacture, use or sale
of the Product infringes a patent or any other proprietary right of the third
party. Such indemnification obligation shall be limited as follows:

           (A)  to the extent such proceeding or settlement thereof results in a
future royalty to be paid by APP, ABI's indemnity obligation shall be satisfied
by having such royalty payment be a deduction from Net Sales; and

           (B)  to the extent such proceeding or settlement thereof results in a
payment obligation other than as provided in Section 21.3(A) above, ABI shall
                                             ---------------
indemnify APP only to the extent of fifty percent (50%) of payments previously
made by APP to ABI pursuant to Section 8.1 of the License Agreement, and any
                               -----------
indemnity payments to be made by ABI to APP or on behalf of APP pursuant to the
foregoing shall be limited to fifty percent (50%) of ABI's operating cash flow,
including without limitation, the split of Gross Profits under the License
Agreement.

     15.4  If any Party entitled to be indemnified pursuant to this Section 15
                                                                    ----------
(an "Indemnified Party") receives notice of the assertion by any Person of any
    ------------------
claim or of the commencement by any such Person of any Action (any such claim or
Action being referred to herein as an "Indemnifiable Claim") with respect to
                                       -------------------
which another Party hereto (an "Indemnifying Party") is or may be obligated to
                                ------------------
provide indemnification, the Indemnified Party must promptly notify the
Indemnifying Party in writing (the "Claim Notice").  The failure to provide such
                                    ------------
notice will not relieve or otherwise affect the obligation of the Indemnifying
Party to provide  indemnification hereunder, except to the extent that any
Damages directly resulted or were caused by such failure.

<PAGE>

     15.5  The Indemnifying Party will have 30 days after receipt of the Claim
Notice to undertake, conduct and control, through counsel of its own choosing
and at its expense, the settlement or defense of the claim, and the Indemnified
Party will cooperate with the Indemnifying Party in connection with the
settlement or defense, if:

           (A)  the Indemnifying Party permits the Indemnified Party to
participate in the settlement or defense through counsel chosen by the
Indemnified Party (subject to the consent of the Indemnifying Party, which
consent shall not be unreasonably withheld);

           (B)  the fees and expenses of such counsel will not be borne by the
Indemnifying Party; and

           (C)  the Indemnifying Party does not settle any Indemnifiable Claim
without the Indemnified Party's consent. So long as the Indemnifying Party is
vigorously contesting any Indemnifiable Claim in good faith, the Indemnified
Party may not pay or settle the claim without the Indemnifying Party's consent,
which consent shall not be unreasonably withheld.

     15.6  If the Indemnifying Party does not notify the Indemnified Party
within 30 days after receipt of the Claim Notice that it elects to undertake the
defense of the Indemnifiable Claim described in the Claim Notice, the
Indemnified Party has the right to contest, settle or compromise the
Indemnifiable Claim in the exercise of its reasonable discretion. However, the
Indemnified Party must notify the Indemnifying Party of any compromise or
settlement of any such Indemnifiable Claim.

     15.7  Notwithstanding anything in this Section 15 to the contrary, APP is
                                            ----------
not entitled to assume the defense for any Indemnifiable Claim (and will be
liable for the reasonable fees and expenses incurred by the Indemnified Party in
defending the claim) if the Indemnifiable Claim seeks an order, injunction or
other equitable relief (or other relief for other than money damages) against
ABI or its Affiliates which ABI determines, after conferring with its counsel,
cannot be separated from any related claim for money damages and which, if
successful, would adversely affect the commercialization of the Product.
However, if an equitable relief portion of the Indemnifiable Claim can be
separated from that for money damages, APP may assume the defense of the portion
relating to money damages.

16.  EXCEPT FOR BODILY INJURY OF A PERSON, NEITHER PARTY WILL BE LIABLE
HEREUNDER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES,
INCLUDING WITHOUT LIMITATION, LOSS OF PROFITS FROM THE USE OF (OR INABILITY TO
USE) THE TECHNOLOGY, THE DEVELOPMENT OR COMMERCIALIZATION OF THE PRODUCT OR
OTHERWISE IN CONNECTION WITH, OR ARISING OUT OF, THIS AGREEMENT.

17.  Miscellaneous Provisions.
     ------------------------

     17.1  Independent Contractors.  ABI and APP are independent parties, and
           -----------------------
nothing contained herein will be construed to create a joint venture,
partnership or similar relationship. Neither Party is authorized to, nor will
it, make any statements, claims, representations,

<PAGE>

warranties or otherwise act in any way so as to incur any liability whatsoever
for which the other Party may become directly, indirectly or contingently
liable.

     17.2  Assignment.

           (A)  The rights and obligations of the Parties under this Agreement
may not be assigned or transferred in any manner, including, without limitation,
by operation of law, sale of stock or sale of assets, without the prior written
approval, which shall not be unreasonably withheld, of the other Party (and any
attempt to do so will be void) except that:

                (1)  rights to payment of money may be assigned without such
approval; and

                (2)  either Party has the right to assign this Agreement to its
lenders as collateral security under a credit facility and following
acceleration of that credit facility, its lender has the right to assign this
Agreement to a third party reasonably satisfactory to the other Party. Despite
the foregoing, in no event will ABI be obligated to consent to an assignment of
this Agreement to a Competitor.

           (B)  Notwithstanding anything to the contrary in Section 17.2(A), if:
                                                            ---------------

                (1)  any Party:

                     (a)  merges or consolidates with any other corporation,
partnership or other business entity; or

                     (b)  has all or substantially all of such Party's business
or assets transferred in any manner to any other corporation, partnership or
other business entity; or

                (2)  any other Person acquires the power, directly or
indirectly, to direct or cause the direction of management and the policies of
such Party (collectively, a "Change of Control");
                             -----------------

such event will be deemed an approved assignment for purposes of this Agreement
if the conditions set forth in Section 17.2(C) are satisfied.
                               ---------------

           (C)  Following a Change of Control, the successor to a Party will
succeed to, and be subject to, all rights, interests, duties and obligations of,
and shall thereafter be deemed for all purposes to be the applicable Party under
this Agreement. To be deemed an approved assignment under this Section 17.2, a
                                                               ------------
successor must:

                (1)  have experience, facilities, capabilities, and financial
resources equal to or greater than such Party; and

                (2)  expressly acknowledge, in a written instrument delivered to
the other Party in a form reasonably acceptable to the Parties the succession to
all duties and obligations of such Party under this Agreement.

<PAGE>

           (D)  Despite the foregoing, for the purposes of this Agreement, an
IPO will not be considered a Change of Control.

     17.3  Notices.  Any and all notices given pursuant to this Agreement shall
           -------
be in writing, and shall be deemed to have been properly given when delivered
personally or sent by facsimile, air courier, or post, to the respective address
shown below or such other address as shall be specified by the Party(ies)
pursuant to written notice given in accordance with this Section 17.3.  Any
                                                         ------------
notice shall be effective upon receipt, which shall be deemed to occur one
business day after the sending of the facsimile is sent, two business days after
the sending by air courier, and five calendar days after the delivery to the US
Postal Service and properly marked and stamped for first class mail, and shall
be sent:

     If to ABI to:

          American BioScience, Inc.
          2730 Wilshire Boulevard
          Santa Monica, California 90403
          Attention:  Chief Executive Officer
          Facsimile:310/998-8553

     With a copy to:


          Attention:
          Facsimile:

     If to APP to:

          American Pharmaceutical Partners, Inc.
          10866 Wilshire Boulevard
          Los Angeles, California 90024
          Attention:  Chief Operating Officer
          Facsimile   310/470-7472

     With a copy to:

          American Pharmaceutical Partners, Inc.
          1101 Perimeter Drive
          Schaumburg, Illinois 60173
          Attention:  General Counsel
          Facsimile   847/413-2670

     17.4  Force Majeure.

           (A)  The obligations of a Party hereunder will be suspended during
the time and to the extent that such Party is prevented from complying therewith
due to any event or circumstances beyond the reasonable control and without the
fault or negligence of the affected

<PAGE>

Party (which circumstance is hereinafter referred to as "Force Majeure"),
                                                         -------------
including but not limited to inevitable accidents, perils of navigation, floods,
fire, storms, earthquakes, lockouts, explosion, hostilities, war (whether
declared or undeclared), acts of terrorism, civil disturbances, order or acts of
any government, whether de jure or de facto or any official purporting to act
under authority of any such government (other than as to regulatory approval),
illegality arising from domestic or foreign laws or regulations, insurrections,
quarantine or custom restrictions (other than due to the action or inaction of
the Party claiming a Force Majeure), damage in factories or warehouses, strikes,
lockouts, or other labor difficulty at the Parties, lack of conveyance,
breakdown of machinery or instruments or other disturbances at the Parties or
their suppliers, shortages or inability to obtain Chemical Ingredients or other
components and raw materials from suppliers, or acts of God or other similar
event beyond the reasonable control of, as the case may be, ABI or APP which
results in hindrance of the performance by the Party of its obligations
hereunder.

           (B)  As soon as possible after being affected by a Force Majeure
circumstance, the affected Party must furnish to the other Party all particulars
of the Force Majeure and the manner in which its performance is thereby
prevented or delayed. The Party whose obligations hereunder have been suspended
will promptly and diligently pursue appropriate action to enable it to lift the
Force Majeure situation, except that Party shall not be obligated to settle any
strike, lockout or other labor difficulty on terms contrary to its wishes.

           (C)  If any Force Majeure circumstance cannot be removed or overcome
within 120 days (or such other period as the Parties mutually agree) from the
date the affected Party first became affected, then the non-affected Party may,
at the expiration of such period, by notice to the affected Party terminate this
Agreement, and neither Party will be liable to the other for damages.

     17.5  Amendment and Waiver.  This Agreement (including the Exhibits hereto)
           --------------------
may be amended, modified, superseded or cancelled, and any other of the terms or
conditions hereof may be modified, only by a written instrument executed by both
Parties or, in the case of a waiver, by the Party waiving compliance. Failure of
either Party at any time or times to require performance of any provision hereof
will in no manner affect the right of such Party at a later time to enforce the
same, and no waiver of any nature, whether by conduct or otherwise, in any one
or more instances, will be deemed to be or considered as a further or continuing
waiver of any provision of this Agreement.

     17.6  Severability.  If any one or more of the agreements, provisions or
           ------------
terms contained herein are declared invalid, illegal or unenforceable in any
respect, the validity of the remaining agreements, provisions or terms contained
will shall in no way be affected, prejudiced or invalidated thereby.

     17.7  Entire Agreement.  This Agreement, together with the Technology Side
           ----------------
Letter, the Exhibits hereto and the separately agreed-upon Specifications,
contains the entire agreement between the Parties, and supersedes any agreements
between them with respect to the subject matter hereof.

<PAGE>

     17.8   Section Headings; Recitals.  The section headings contained in this
            --------------------------
Agreement are for reference purposes only and will not affect in any way the
meaning or interpretation of this Agreement.  The recitals are hereby
incorporated into this Agreement by reference.

     17.9   Governing Law.  This Agreement shall be governed by and construed
            -------------
and enforced in accordance with the substantive law (without regard to conflicts
of law provisions) of the State of California.

     17.10  Arbitration; Equitable Relief.
            -----------------------------

            (A)  Except in the case of a Party seeking equitable relief
hereunder, any and all disputes or controversies, whether of law or fact and of
any kind and nature whatsoever, arising out of or relating to this Agreement,
will be decided by binding arbitration in accordance with Title 9 of the United
States Code and the Commercial Arbitration Rules of the American Arbitration
Association ("AAA"). For claims under $1,000,000 the arbitration will be held
              ---
before a single arbitrator. If the Parties are unable to agree on an arbitrator,
the arbitration will be before an arbitrator selected by AAA. For claims over
$1,000,000 the arbitration will be held before a three-member panel of
arbitrators. If the Parties are unable to agree on a three-member panel of
arbitrators, the arbitration will be before a three-member panel of arbitrators
selected by AAA. Arbitration shall take place in Los Angeles County, State of
California, or such other location as may be agreed by the Parties. Claims with
respect to injunctive relief or specific performance will be resolved by a court
of law in accordance with Section 17.10(B). APP irrevocably consents and submits
                          -----------------
to personal jurisdiction in the State of California for any arbitration
contemplated by this Section 17.10. The decision of the arbitrators will be
                     -------------
binding upon the Parties hereto and all Parties claiming under and through them,
and judgment will be entered by any court of competent jurisdiction. The fees
and expenses of the arbitrator will be paid equally by the Parties.

            (B)  With respect to actions for injunctive relief and specific
performance, the Parties submit to the jurisdiction of any state or federal
court sitting in Los Angeles County in any Action arising out or respecting this
Agreement and agree that all claims in respect of such Action shall be heard and
determined in any such court. The Parties waive any defense of inconvenient
forum to the maintenance of any Action and waive any bond, surety or other
security that may be required of any other Party with respect to the Action. The
Parties agree that a final judgment in any Action brought under this Section
17.10(B) will be conclusive. Either Party may seek injunctive relief if any
-------
provision of this Agreement is not performed in accordance with its terms and
for which such Party would not have an adequate remedy for money damages. Any
such remedy will be in addition to any other remedy that may be available at law
or equity.

     17.11  No Strict Construction.  The language used in this Agreement will be
            ----------------------
deemed to be the language chosen by the Parties hereto to express their mutual
intent, and no rule of strict construction will apply to any term or condition
of this Agreement.

     17.12  Survival.  Except to the extent that any monies are owed and not
            --------
yet paid and for the provisions of Sections 8, 9, 10, 11, 12, 13, 15, 16, 17.3,
                                   ----------  -  --  --  --- --  --  --  ----
17.9, 17.10 and 17.12, none of the provisions herein shall survive Termination.
----  -----     -----

<PAGE>

     17.13  Counterparts.  This Agreement may be executed in separate
            ------------
counterparts, each of which will be deemed to be an original, but which together
will constitute one and the same instrument.

                  [REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date and year first written above.

                                    AMERICAN BIOSCIENCE, INC.

                                    By:  /s/ Patrick-Soon Shiong
                                         ---------------------------------
                                    Patrick Soon-Shiong
                                    President

                                    AMERICAN PHARMACEUTICAL PARTNERS, INC.

                                    By:  /s/ Jeffrey M. Yordon
                                         ---------------------------------
                                    Jeffrey M. Yordon
                                    Chief Operating Officer

<PAGE>

                                   EXHIBIT A

                                 ABI Insurance

                 $25,000,000 per incident and in the aggregate

<PAGE>

                                   EXHIBIT B

                                 APP Insurance

                 $25,000,000 per incident and in the aggregate